Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Extrapulmonary Neuroendocrine Carcinoma”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Testing effectiveness (Phase 2)Study completedNCT04705519
What this trial is testing

Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma

Who this might be right for
Neuroendocrine Carcinoma
Peking University 79
Testing effectiveness (Phase 2)Active Not RecruitingNCT03896503
What this trial is testing

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Who this might be right for
Extensive Stage Lung Small Cell CarcinomaExtrapulmonary Small Cell Neuroendocrine CarcinomaLimited Stage Lung Small Cell Carcinoma+3 more
National Cancer Institute (NCI) 104
Large-scale testing (Phase 3)Looking for participantsNCT05058651
What this trial is testing

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Who this might be right for
Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI)
Early research (Phase 1)Not Yet RecruitingNCT07509034
What this trial is testing

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

Who this might be right for
Extensive-Stage Small Cell Lung CancerExtrapulmonary Neuroendocrine CarcinomaRecurrent or Refractory+1 more
National Cancer Institute (NCI) 40
189